ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
2seventy bio Inc

2seventy bio Inc (TSVT)

3.96
0.27
(7.32%)
Closed 29 November 8:00AM
3.96
-0.01
(-0.25%)
After Hours: 11:37AM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.951.751.151.350.000.00 %0153-
5.000.050.100.100.0750.05100.00 %201,24028/11/2024
7.500.000.000.000.000.000.00 %00-

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.050.100.050.0750.000.00 %078-
5.001.001.701.051.35-0.35-25.00 %118228/11/2024
7.500.000.000.000.000.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VCIGVCI Global Ltd
US$ 4.1092
(129.56%)
257.18M
IDAIT Stamp Inc
US$ 0.835
(128.77%)
369.69M
WAITop KingWin Ltd
US$ 0.43
(79.17%)
121.91M
HWHHWH International Inc
US$ 0.918
(62.48%)
32.06M
PROCProcaps Group SA
US$ 2.149
(58.01%)
210.26k
PGHLPrimega Group Holdings Ltd
US$ 1.6455
(-98.47%)
43.2M
OTLKOutlook Therapeutics Inc
US$ 1.695
(-65.34%)
61.98M
IMGCIMG Inc
US$ 0.8831
(-44.81%)
5.22M
KDLYKindly MD Inc
US$ 1.075
(-43.12%)
3.54M
HAOHaoxi Health Technology Ltd
US$ 0.13
(-36.59%)
36.86M
IDAIT Stamp Inc
US$ 0.835
(128.77%)
374.4M
VCIGVCI Global Ltd
US$ 4.1092
(129.56%)
257.58M
NVDANVIDIA Corporation
US$ 135.34
(-1.15%)
226.41M
WAITop KingWin Ltd
US$ 0.43
(79.17%)
121.92M
MARAMARA Holdings Inc
US$ 26.915
(7.79%)
87.94M

TSVT Discussion

View Posts
Monksdream Monksdream 3 months ago
TSVT under $5
👍️0
Monksdream Monksdream 7 months ago
TSVT under $5
👍️0
Invest-in-America Invest-in-America 8 months ago
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 9 months ago
TSVT 10Q due March 5
👍️0
molee molee 10 months ago
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 11 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1
johnhancoque johnhancoque 1 year ago
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 1 year ago
C'mon man . What the heck . $2.00 now ? Really ?
👍️0

Your Recent History

Delayed Upgrade Clock